InMed Pharmaceuticals Inc. has filed a Form 8-K with the Securities and Exchange Commission (SEC) on April 3, 2026, to report the sale of its common shares under an At The Market Offering Agreement. This agreement, originally dated April 7, 2022, was amended on June 27, 2024, and allows the company to sell shares in accordance with its shelf registration statement on Form S-3, which was declared effective by the SEC on March 30, 2026. The filing includes a prospectus supplement related to the sale of common shares, indicating the company is actively seeking to raise capital through this method. The legal opinion regarding the legality of the securities being registered is also included in the filing as Exhibit 5.1. This move is expected to provide InMed with additional liquidity to support its ongoing operations and strategic initiatives.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.